San Diego-based Viking Therapeutics marked alone as a serious competitor inside the weight loss drug current market in February following revealing promising knowledge from a mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection and in March the company